Puma Biotechnology Q4 2025 slides: NERLYNX revenue rises 15% sequentially

Net NERLYNX revenue was $59.9M in Q4'25 (+15% sequential, +10% YoY), driving total company revenue of $75.5M and a third consecutive year of profitability. Volume rose to 3,298 ex-factory bottles (+11% YoY, +12% QoQ) and royalty revenue jumped to $15.6M from $2.6M in Q3'25, but management reported declines in new prescriptions and patient enrollments and the stock fell ~3.03% after the release. Management guided Q2'26 revenue of ~$52M and Q3'26 of ~$60.5M with EPS estimates of $0.07 and $0.22, indicating modest near-term growth yet raising sustainability concerns given prescription headwinds.

Analysis

The recent quarter looks like a classic revenue pull-forward: elevated channel inventories plus lumpy international royalties can mask weakening underlying demand. Expect an inventory unwind and a reversion in sequential revenue growth in the next 1–2 quarters as wholesalers and specialty pharmacies normalize stocking levels, creating a near-term earnings miss risk despite longer-term profitability signals.

Widespread adoption of reduced‑dose initiation is a structural double‑edged sword — it materially improves persistence and lowers discontinuation, but it also compresses revenue per treated patient and increases the importance of unit volume growth to sustain top‑line expansion. Over a multi‑quarter horizon this shifts the KPI investors should watch from headline revenue to new‑prescription trends, average pills/bottle per patient, and treatment duration metrics; a sustained decline in new starts would be a higher‑impact negative than temporary inventory swings.

Second‑order winners and losers are non-obvious: specialty pharmacy hubs and large distributors gain short‑term revenue/working‑capital benefits from stocking and patient-support programs, while pure play oncology launches without international royalty exposure will show more volatility. Payer behavior and competitor launches (including lower‑cost alternatives) are the real medium‑term threats — if payers lean into step‑therapy or substitute biologics, revenue sustainability will be impaired even as persistence improves.

Key Decisions for Investors

• Tactical bearish: Buy 3–6 month PBYI puts sized to 2–3% portfolio risk ahead of the next two quarterly prints to capture downside from expected inventory destocking and declining new‑patient starts. Rationale: limited time premium, direct hedge to short‑term earnings risk; monitor new‑prescription cadence and specialty pharmacy inventory disclosures as exit signals.
• Relative pair: Short PBYI equity and simultaneously go long MCK (or CAH) for 6–12 months. Rationale: distributors should hold or gain margin from fulfillment and stocking volatility while PBYI faces demand reversion and revenue per patient compression. Position size modest (net delta neutral) to limit market beta exposure.
• Event‑driven optionality: If you want asymmetric upside but limited downside, buy a 9–12 month PBYI call spread (long lower strike, short higher strike) sized small. Rationale: captures upside from sustained international royalty cadence or positive pipeline readouts without full equity exposure; exit on confirmed acceleration in new prescription flow or a positive clinical/corporate catalyst.
• Defensive long: Add exposure to CVS (specialty pharmacy vertical) for 6–12 months to play steadier cash flows from hub services and specialty dispensing. Rationale: benefits from hub/channel stickiness and will likely see stable fill volumes even as single‑drug volatility impacts manufacturers; use as hedge against biopharma idiosyncratic shocks.